1
|
Ge Q, Zhao J, Qu F. Investigating the progression of preeclampsia through a comprehensive analysis of genes associated with per- and polyfluoroalkyl substances. Toxicol Mech Methods 2024; 34:444-453. [PMID: 38166544 DOI: 10.1080/15376516.2023.2299485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 12/19/2023] [Indexed: 01/04/2024]
Abstract
Per- and Polyfluoroalkyl Substances (PFAS) are synthetic chemicals utilized in the production of various products that possess water and dirt-repellent properties. Exposure to PFAS has been linked to numerous diseases, such as cancer and preeclampsia (PE). However, whether PFAS contributes to the advancement of PE remains uncertain. In this study, we conducted an extensive bioinformatics analysis using the Comparative Toxicogenomics Database (CTD) and Gene Expression Omnibus (GEO) databases, leading us to discover a connection between PE and four specific PFAS. Moreover, further examination revealed that six genes associated with PFAS exhibited significant diagnostic potential for individuals with PE. By employing receiver operating characteristic (ROC) curves, our PFAS-related gene-based nomogram model demonstrated outstanding predictive efficacy for diagnosing PE. Immune infiltration analysis showed that six PFAS-related genes were significantly associated with the level of immune cell infiltration. The expression of PFAS-related genes in PE patients was confirmed by collecting clinical samples. This research has offered fresh perspectives on comprehending the impact of PFAS on PE, drawing attention to the connection between environmental factors and the risks and development of PE.
Collapse
Affiliation(s)
- Qiuyan Ge
- Department of Obstetrics, Nantong Tongzhou People's Hospital, Nantong, China
| | - Ju Zhao
- Department of Obstetrics, Nantong Tongzhou People's Hospital, Nantong, China
| | - Fujuan Qu
- Department of Obstetrics, Nantong Tongzhou People's Hospital, Nantong, China
| |
Collapse
|
2
|
Moder JE, Ordenewitz LK, Schlüter JA, Weinmann T, Altebäumer P, Jung J, Heinen F, Landgraf MN. [Fetal alcohol spectrum disorders-diagnosis, prognosis, and prevention]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021; 64:747-754. [PMID: 33942146 PMCID: PMC8187172 DOI: 10.1007/s00103-021-03329-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 03/19/2021] [Indexed: 11/23/2022]
Abstract
Die Fetale Alkoholspektrumstörung ist eine der häufigsten bei Geburt bestehenden chronischen Erkrankungen, die zum Großteil nicht oder fehldiagnostiziert wird. Dies führt zu inadäquater, ineffektiver Förderung und Therapie der erkrankten Kinder sowie mangelnder Unterstützung der betroffenen Familien. Daraus resultiert nicht nur ein hohes Maß an Sekundärerkrankungen, sondern auch eine Einbuße in der Möglichkeit der Sekundär- und Tertiärprävention bei erkrankten Kindern und betroffenen Familien. Sekundär und Tertiärprävention sind jedoch bei richtiger und rechtzeitiger Diagnose möglich. Die Primärprävention im Bereich Alkoholkonsum in der Schwangerschaft und Fetale Alkoholspektrumstörung muss auch in Zukunft sowohl von medizinischer als auch politischer Seite strukturiert, interdisziplinär und wissenschaftlich basiert geplant und durchgeführt werden. Neben der Aufklärung der Allgemeinbevölkerung ist hierbei die Wissensvermittlung an ÄrztInnen und andere medizinisch-psychologisch-pädagogische Fachkräfte besonders relevant.
Collapse
Affiliation(s)
- Judith E Moder
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland
| | - Lisa K Ordenewitz
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland.,Abteilung Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, München, Deutschland
| | - Julia A Schlüter
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland.,Abteilung Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, München, Deutschland
| | - Tobias Weinmann
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland.,Institut und Poliklinik für Arbeits‑, Sozial- und Umweltmedizin, LMU Klinikum München, München, Deutschland
| | - Philine Altebäumer
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland
| | - Jessica Jung
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland.,Abteilung Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, München, Deutschland
| | - Florian Heinen
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland.,Abteilung Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, München, Deutschland
| | - Mirjam N Landgraf
- Deutsches FASD KOMPETENZZENTRUM Bayern, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, Lindwurmstraße 4, 80337, München, Deutschland. .,Abteilung Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, LMU Zentrum für Entwicklung und komplex chronisch kranke Kinder - iSPZ Hauner, Dr. von Haunersches Kinderspital, LMU Klinikum München, München, Deutschland.
| |
Collapse
|
3
|
Helgesson G, Bertilsson G, Domeij H, Fahlström G, Heintz E, Hjern A, Nehlin Gordh C, Nordin V, Rangmar J, Rydell AM, Wahlsten VS, Hultcrantz M. Ethical aspects of diagnosis and interventions for children with fetal alcohol Spectrum disorder (FASD) and their families. BMC Med Ethics 2018; 19:1. [PMID: 29304784 PMCID: PMC5755211 DOI: 10.1186/s12910-017-0242-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Accepted: 12/26/2017] [Indexed: 11/10/2022] Open
Abstract
Background Fetal alcohol spectrum disorders (FASD) is an umbrella term covering several conditions for which alcohol consumption during pregnancy is taken to play a causal role. The benefit of individuals being identified with a condition within FASD remains controversial. The objective of the present study was to identify ethical aspects and consequences of diagnostics, interventions, and family support in relation to FASD. Methods Ethical aspects relating to diagnostics, interventions, and family support regarding FASD were compiled and discussed, drawing on a series of discussions with experts in the field, published literature, and medical ethicists. Results Several advantages and disadvantages in regards of obtaining a diagnosis or description of the condition were identified. For instance, it provides an explanation and potential preparedness for not yet encountered difficulties, which may play an essential role in acquiring much needed help and support from health care, school, and the social services. There are no interventions specifically evaluated for FASD conditions, but training programs and family support for conditions with symptoms overlapping with FASD, e.g. ADHD, autism, and intellectual disability, are likely to be relevant. Stigmatization, blame, and guilt are potential downsides. There might also be unfortunate prioritization if individuals with equal needs are treated differently depending on whether or not they meet the criteria for a specific condition. Conclusions The value for the concerned individuals of obtaining a FASD-related description of their condition – for instance, in terms of wellbeing – is not established. Nor is it established that allocating resources based on whether individuals fulfil FASD-related criteria is justified, compared to allocations directed to the most prominent specific needs.
Collapse
Affiliation(s)
- Gert Helgesson
- Stockholm Centre for Healthcare Ethics (CHE), Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.
| | - Göran Bertilsson
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden
| | - Helena Domeij
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden
| | - Gunilla Fahlström
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden
| | - Emelie Heintz
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.,Medical Management Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
| | - Anders Hjern
- Clinical Epidemiology, Department of Medicine, Karolinska Institutet and Center for Health Equity Studies, Stockholm, Sweden
| | | | - Viviann Nordin
- Center of Neurodevelopmental Disorders, Karolinska Institutet (KIND), Stockholm, Sweden
| | - Jenny Rangmar
- Department of Psychology, University of Gothenburg, Gothenburg, Sweden
| | | | - Viveka Sundelin Wahlsten
- Department of Neuroscience, Child and Adolescent Psychiatry, Uppsala University, Uppsala, Sweden
| | - Monica Hultcrantz
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.,Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|